论文部分内容阅读
目的 探寻促甲状腺激素受体抗体 (TRAb)与Graves病 (GD)的关系 ,了解TRAb活性与甲状腺功能亢进症的内在联系。 方法 采用放射受体分析法检测GD患者 (分甲亢组和缓解组 )以及健康人血清TRAb。 结果 GD甲亢组、缓解组及正常对照组的TRAb活性分别为 2 8.3± 2 2 .1,5 .6± 3.2和1.8± 0 .9U/L ;GD组明显高于正常对照组 ,GD甲亢组明显高于缓解组。GD甲亢组TRAb、甲状腺球蛋白抗体 (TGAb)、甲状腺微体抗体 (TMAb)阳性检出率分别为 81.4%、6 0 .5 %和 5 3.5 %。GD患者血清TRAb活性与FT3,FT4 及TSH浓度之间均无显著相关性。 结论 检测TRAb不能反映GD甲亢严重程度 ,但对了解GD的发病机理及合理诊治具有重要临床价值
Objective To investigate the relationship between thyrotropin receptor antibody (TRAb) and Graves’ disease (GD) and to understand the intrinsic relationship between TRAb activity and hyperthyroidism. Methods Radioimmunoassay was used to detect the serum levels of TRAb in GD patients (sub-hyperthyroidism group and remission group) and healthy subjects. Results The activity of TRAb in GD hyperthyroidism group, remission group and normal control group were respectively 2 8.3 ± 2 2 .1,5 .6 ± 3.2 and 1.8 ± 0.9U / L; GD group was significantly higher than that in normal control group and GD hyperthyroidism group Significantly higher than the remission group. The positive rates of TRAb, TGAb and TMAb in GD hyperthyroidism group were 81.4%, 65.5% and 53.5% respectively. There was no significant correlation between serum TRAb level and the concentrations of FT3, FT4 and TSH in GD patients. Conclusion The detection of TRAb can not reflect the severity of GD hyperthyroidism, but it has important clinical value in understanding the pathogenesis of GD and its reasonable diagnosis and treatment